热门资讯> 正文
Syndax获得Revuforj治疗急性骨髓性白血病的额外适应症
2025-10-25 01:53
- 纳比特(NA) 0
- 盛大科技(SDA) 0
- Syndax制药(SNDX) 0
- The US FDA has approved Syndax Pharmaceuticals' (NASDAQ:SNDX) Revuforj (revumenib) for relapsed or refractory acute myeloid leukemia in patients with a certain genetic mutation.
- The indication is for individuals with the disease who have the susceptible nucleophosmin 1 (NPM1) mutation and no other treatment options.
- Revuforj was first approved in 2024 for relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.
- The menin inhibitor's new indication was granted based on results from a single-arm cohort of an open-label trial. The complete remission with partial hematological recovery rate was 23.1% and the median duration was 4.5 months.
More on Syndax Pharmaceuticals
- Making Money In Biotech Stocks
- Syndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRC
- Syndax Pharmaceuticals, Inc. (SNDX) Presents At Citi's Biopharma Back To School Conference Transcript
- Syndax resumed with Buy at Stifel on newly launched drugs
- Syndax jumps after Q2 beat; Citi issues upside catalyst watch
推荐文章
美股机会日报 | 金价再度走弱！现失守4030美元；中美贸易争端缓和，纳指期货涨超1%
IBM、AMD双双大涨近8%！量子计算概念再起飞，下一个赢家是谁？
新股暗盘 | 滴普科技涨近50%，中签一手账面浮盈2660港元
新股暗盘 | 八马茶业涨79.00%，中签一手账面浮盈3950港元
美股波动中的稳健长跑选手：华尔街押注Pinterest(PINS.US)、Uber(UBER.US)与通用汽车(GM.US)
黄金火爆行情带热招聘市场 对冲基金、贸易商高薪争夺交易人才
迷雾中前行！美联储本周料将再度降息 内部分歧恐进一步加剧？
新股申购 | “首家A+H豪华新能源车企”赛力斯今起招股，一手入场费13282.62港元
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
